Interstitial pneumonitis related to flutamide monotherapy for prostate cancer

Int J Urol. 2004 Sep;11(9):798-800. doi: 10.1111/j.1442-2042.2004.00882.x.

Abstract

A 88-year-old man with prostate cancer was receiving non-steroidal anti-androgen therapy (flutamide, 375 mg/day). Three weeks after starting therapy, the patient developed dyspnea and bilateral pulmonary interstitial infiltrates. The withdrawal of flutamide and the initiation of steroid therapy resulted in clinical improvement.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal / adverse effects*
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Flutamide / adverse effects*
  • Flutamide / therapeutic use
  • Humans
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Diseases, Interstitial / diagnostic imaging
  • Male
  • Prednisolone / therapeutic use
  • Prostatic Neoplasms / drug therapy*
  • Radiography, Thoracic
  • Retreatment
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents, Hormonal
  • Flutamide
  • Prednisolone